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Healthcare-Associated Infections-Community Interface (HAIC): 
Emerging Infections Program (EIP) Network Report 
Invasive Staphylococcus aureus, 2016
 
HAIC Areas 
 
Methicillin-resistant Staphylococcus aureus (MRSA): California (3 county San Francisco Bay area); Connecticut; Georgia (8 county Atlanta area); 
Maryland (Baltimore City and County); Minnesota (2 metro Twin City counties); New York (1 Rochester county); Tennessee (1 Nashville county).   
Note: The population under surveillance changed from 2015; it was increased by 2 Maryland counties. 
 
Methicillin-sensitive Staphylococcus aureus (MSSA):  California (3 county San Francisco Bay area); Georgia (1 Atlanta county); Minnesota (2 metro 
Twin City counties); New York (1 Rochester county); Tennessee (1 Nashville county). 
Note: 2016 was the first year of MSSA surveillance. 
 
HAIC Population 
The MRSA surveillance areas represent 15,918,111 persons.  The MSSA surveillance areas represent 7,809,686 persons. 
Source: National Center for Health Statistics bridged-race vintage 2016 postcensal file.   
 
HAIC Case Definition 
Invasive Staphylococcus aureus (SA) disease:  isolation of SA from a normally sterile site in a resident of the surveillance area in 2016.  Cases of disease 
are classified into one of three epidemiologic classifications.  A case is classified as hospital-onset (HO) if the SA culture was obtained on or after the 
fourth calendar day of hospitalization, where admission is hospital day 1;  as healthcare-associated community-onset (HACO) if the culture was 
obtained in an outpatient setting  or before the fourth calendar day of hospitalization and had one or more of the following: 1) a history of 
hospitalization, surgery, dialysis, or residence in a long term care facility in the previous year, or 2) the presence of a central vascular catheter (CVC) 
within 2 days prior to MRSA culture; and as community-associated (CA) if none of the previously mentioned criteria are met.  Cases were classified 
as MRSA or MSSA based on results from local clinical microbiology laboratory testing. 
 
HAIC Methodology 
EIP personnel routinely contacted all microbiology laboratories serving healthcare facilities in their area to identify cases. Standardized case report 
forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case.   
 
Convenience samples of MRSA isolates were collected and sent to CDC for routine testing, including antimicrobial susceptibility testing using 
reference broth microdilution, toxin testing, SCCmec typing, and spa typing. Pulsed field gel electrophoresis (PFGE) of all isolates was discontinued in 
2008; up until 2012, PFGE was inferred based on a validated algorithm (http://www.cdc.gov/HAI/settings/lab/inferred-PFGE-algorithm.html).  
Starting in 2012, spa typing was added to the routine laboratory testing.  Pulsed field type is currently inferred based on spa type, inferred multilocus 
sequence typing (MLST) clonal complex and molecular characteristics of the isolates (http://www.cdc.gov/HAI/settings/lab/CCalgorithm.html).  
Isolates identified as USA300 were confirmed using a SNP assay (https://msphere.asm.org/content/msph/3/3/e00464-17.full.pdf).  In 2016, isolates 
were only collected in three sites (Georgia, Minnesota, and Tennessee). Regular laboratory audits were performed at all sites to ensure completeness 
of case detection.  
 
In 2016, some sites collected limited data from most MRSA hospital-onset cases, with full case report form data collected only for a random sample 
of 12–32% of hospital-onset cases.  Data not collected because of sampling were estimated based on the distribution of collected data to calculate 
incidence.  Detailed case data below only reflect data from full case report forms unless otherwise specified.  Rates of invasive SA disease among all 
patients were calculated using population estimates for 2016.  One site started MSSA surveillance in March 2016.  For rate calculations, case counts 
from this site were multiplied by 1.2 to approximate a full year of surveillance.  Cases with unknown race were assigned race based on distribution 
of known age, race, and gender by EIP site.   
 
Rates of invasive SA disease among patients who were undergoing chronic dialysis treatment were calculated using the December 31, 2015 point 
prevalent counts of patients on dialysis from the United States Renal Data System (USRDS) (http://www.usrds.org/adr.htm).   The figures depicting 
the incidence of invasive MRSA among persons on dialysis and not on dialysis by epidemiologic classification, 2009–2016 are restricted to the 
continuous catchment area (California [3 county San Francisco Bay area]; Connecticut; Georgia [8 county Atlanta area]; Minnesota [1 metro Twin City 
county]; New York [1 Rochester county]; and Tennessee [1 Nashville county]) for comparison of trends over time. 
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HAIC Results 
 
MSSA and MRSA Casesa By Race 
Race MSSA No. (Rateb) MRSA No. (Rateb) 
White 1551 (31.2) 1972 (19.5) 
Black 584 (41.5) 1134 (30.3) 
Other 311 (31.3) 108 (5.4) 
TOTAL 2446 (31.3) 3214 (20.2) 
Unknown race (n= 238 MSSA, N=197 MRSA) distributed amongst 
known 
aMSSA case counts multiplied by 1.2 for one site 
b Cases per 100,000 population for EIP areas (crude rates) 
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MSSAa and MRSA Case and Death Rate by Epidemiological Classification 
     
Class No. (Rateb) 
MSSA Cases  
No. (Rate) 
MSSA Deaths  
No. (Rate) 
MRSA Cases  
No. (Rate) 
MRSA Deaths  
CA 910 (12.2) 74 (1.0) 746 (4.7) 65 (0.4) 
HCAc 1495 (19.2) 175 (2.3) 2408 (15.1) 384 (2.4) 
     HOd 279 (3.6) 44 (0.6) 510 (3.2) 110 (0.7) 
     HACO 1216 (15.6) 131 (1.7) 1898 (11.9) 274 (1.7) 
Unknown 41 (0.5) 8 (0.1) 60 (0.4) 10 (0.06) 
a MSSA case counts multiplied by 1.2 for one site 
b Cases per 100,000 population for EIP areas (crude rates) calculated using 2016 U.S. Census Data 
c HCA: Healthcare-associated invasive SA infection; sum of patients that are classified as either the HO or HACO classes 
d HO MRSA rate imputed from a sample of cases. 
 
 
MRSA Inferred PFGE Type by Epidemiological Classification, isolates tested at CDC 
  CC5 CC8 Other (not CC5 
or CC8) 
Class Total USA100 
No. (%) 
Other CC5  
No. (%) 
USA300 
No. (%) 
Other CC8 
No. (%) 
 
No. (%) 
CA 104 18 (17.3) 12 (11.5) 57 (54.8) 3 (2.9) 14 (13.5) 
HCAa  322 118 (36.6) 10 (3.1) 118 (36.6) 25 (7.8) 51 (15.8) 
     HO 58 20 (34.5) 1 (1.7) 25 (43.1) 7 (12.1) 5 (8.6) 
     HACO 264 98 (37.1) 9 (3.4) 95 (36.0) 25 (9.5) 37 (14.0) 
Totalb 429 137 (31.9) 22 (5.1) 179 (41.7) 35 (8.2) 56 (13.1) 
a HCA: Healthcare-associated invasive MRSA infection; sum of patients that are classified as either the HO or HACO classes 
b n= 3 epidemiologic category unknown 
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MRSA antimicrobial susceptibility testing results by agenta,b (n=429 isolates tested at CDC) 
 
a High level mupirocin resistance depicted in the figure as resistant; non-high level mupirocin resistance shown as susceptible. 
b Daptomycin non-susceptible isolates are depicted in the figure as resistant; isolates with inducible resistance to clindamycin are considered resistant 
c Trimethoprim-Sulfamethoxazole 
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Reported MSSA (n=314) and MRSA (n=441) Cases on Chronic Dialysis  
Dialysis and Access Type MSSA No.  (%) MRSA No. (%) 
Type of dialysis    
      Peritoneal  24 ( 7.6)  12 (2.7) 
      Hemodialysisa  287 (91.4)  425 (96.3) 
AV Fistula/Graft  163 (56.7)      182 (42.8) 
CVC  121 (42.1)      230 (54.1) 
Unknown  4 (1.4)      13 (3.1) 
      Unknown  3 (1.0) 4 (0.9) 
a One MSSA patient had AV Fistula/Graft and CVC 
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Reported MSSA and MRSA Clinical Syndrome by Epidemiological Class, 2016 
   
 CA HACO HO 
Syndrome a 
MSSA 
(n=899) 
MRSA 
(n=746) 
MSSA 
(n=1201) 
MRSA 
(n=1898) 
MSSA 
(n=276) 
MRSA 
(n=154)b 
 No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Bloodstream Infection c          
with other syndrome 451 (50.2) 476 (63.8) 593 (59.6) 1045 (55.1) 127 (46.0) 65 (42.2) 
with no other syndrome 222 (24.7) 141 (18.9) 402 (40.4) 652 (38.4) 76 (27.5) 51 (33.1) 
Pneumonia 77 (8.6) 93 (12.5) 94 (7.8) 220 (11.6) 21 (7.6) 21 (13.6) 
Osteomyelitis 132 (14.7) 102 (13.7) 128  (10.7) 249  (13.1) 31 (11.2) 14 (9.1) 
Endocarditis 71  (7.9) 67 (9.0) 52 (4.3) 131 (6.9) 7 (2.5) 8 (5.2) 
Cellulitis 160 (17.8) 169  (22.7) 127  (10.6) 193 (10.2) 19 (6.9) 9 (5.8) 
Wounds        
Surgical d 5 (0.6) 11 (1.5) 75 (6.2) 91 (4.8) 7 (4.6) 4 (1.5) 
Decubitus/Pressure Ulcers 2 (0.2) 10 (1.3) 19 (1.6) 33 (1.7) 4 (2.6) 4 (1.5) 
Skin Abscesses e 38 (4.2) 75 (10.1) 30 (2.5) 48 (2.5) 2 (1.3) 3 (1.1) 
Other Wounds f 20 (2.2) 17 (2.3) 32 (2.7) 74 (3.9) 1 (0.7) 2 (0.7) 
Traumatic 7 (0.8) 10 (1.3) 3 (0.3) 4 (0.2) 2 (1.3) 4 (1.5) 
a Some case patients had more than one syndrome. 
b Represents a subset of HO MRSA cases due to sampling 
c Catheter site infection or AV fistula infection only are included in BSI with other syndrome. 
d Combines deep tissue/organ infection and infection of a surgical wound, post-operatively. 
e Category includes skin abscess, necrotizing fasciitis, gangrene. 
f Category includes non-traumatic and other chronic wound infections.  
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a Incidence (no. per 100,000 population per year) calculated using 2016 U.S. Census Data  
b MSSA case counts multiplied by 1.2 for one site 
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a Restricted to the continuous catchment area (California [3 county San Francisco Bay area]; Connecticut; Georgia [8 county Atlanta area]; Minnesota [1 metro Twin 
City county]; New York [1 Rochester county]; and Tennessee [1 Nashville county]) for comparison of trends over time.  
0
5
10
15
20
25
2009 2010 2011 2012 2013 2014 2015 2016In
cid
en
ce
 p
er
 1
00
,0
00
 n
on
-d
ia
ly
sis
 
po
pu
la
tio
n
Year
Incidence of Invasive MRSA Among Persons Not on Dialysis by 
Epidemiologic Class, 2009–2016a
Overall CA HACO HO
Number and Incidence Rates of Invasive MRSA and MSSAa Infections by Dialysis Status and Epidemiologic Category, 2016 
Epidemio
gic 
Category 
Dialysis Status 
Dialysis Patientsb Non-Dialysis Patientsc Total 
MSSA MRSA MSSA MRSA MSSA MRSA 
 No. Incidence 
Rate 
No. Incidence 
Rate 
No. Incidence 
Rate 
No. Incidence 
Rate 
No. Incidence 
Rate 
No. Incidence 
Rate 
CA 0 0 0 0 910 11.67 746 4.7 910 11.65 746 4.7 
HCAd 318 2552.99 503 1940.4 1177 15.10 1905 12.0 1495 19.15 2408 15.1 
    HOe 22 178.23 77 297.0 257 3.3 433 2.7 279 3.58 510 3.2 
    HACO 296 2374.76 426 1643.4 920 11.80 1472 9.3 1216 15.57 1898 11.9 
Overall 318 2552.99 503 1940.44 2128 27.29 2711 17.06 2446 31.32 3214 20.2 
a MSSA case counts multiplied by 1.2 for one site  
b Incidence (no. per 100,000 dialysis patients per year) for dialysis patients calculated using 2015 USRDS point prevalence data  
c  Incidence (no. per 100,000 population per year) calculated using 2016 U.S. Census Data  
d HCA: Healthcare-associated invasive MRSA infection; sum of patients that are classified as either the HO or HACO classes 
e Dialysis and non-dialysis estimated number and incidence based on data from a sample of HO MRSA cases. 
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a Restricted to the continuous catchment area (California [3 county San Francisco Bay area]; Connecticut; Georgia [8 county Atlanta area]; Minnesota [1 metro Twin 
City county]; New York [1 Rochester county]; and Tennessee [1 Nashville county]) for comparison of trends over time. 
Brief Summary 
Surveillance data from 2016 represents the twelfth full year of performing population-based surveillance for invasive MRSA infections through the 
Emerging Infections Program, and the first for MSSA.  Incidence of invasive HCA MRSA has decreased since 2009.  
Reported invasive MSSA incidence was greater than invasive MRSA incidence for every age group, race category, and epidemiologic classification. 
Citation 
1. Centers for Disease Control and Prevention. 2016. Healthcare-Associated Infections – Community Interface Surveillance Report, Emerging 
Infections Program Network, Methicillin-Resistant Staphylococcus aureus, 2016.  Available via the Internet: https://www.cdc.gov/hai/eip/pdf/2016-
MRSA-Report-P.pdf 
For more information, visit our web sites:  https://www.cdc.gov/hai/eip/saureus.html, http://www.cdc.gov/mrsa
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